<DOC>
	<DOCNO>NCT01795313</DOCNO>
	<brief_summary>The purpose study see vaccination HLA-A2 restrict peptide , combine immunoadjuvant imiquimod safe induce immune responses child recurrent ependymomas . Eligible patient stratiﬁed primary tumor location .</brief_summary>
	<brief_title>Immunotherapy Recurrent Ependymomas Children Treatment Recurrent Ependymomas Using HLA-A2 Restricted Tumor Antigen Peptides Combination With Imiquimod</brief_title>
	<detailed_description />
	<mesh_term>Ependymoma</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>All grade ependymoma eligible . Patients must recurrent/progressive ependymoma progress recurred initial adjuvant therapy . HLAA2 positive base flow cytometry perform University Pittsburgh . Patients must previously receive standard initial therapy include attempt gross total resection , safely feasible , appropriate circumstance ( e.g. , old one year initial diagnosis , nonmetastatic tumor least microscopic residual disease ) , involved field fractionate radiation therapy ( RT ) . Patients may receive reirradiation index lesion within 4 week . Patients must clinically stable lowdose ( 0.1 mg/kg/day , max 4 mg/day Dexamethasone ) corticosteroid least one week prior study registration . Patients must ≥ 12 month &lt; 22 year age time study registration . Patients must performance status ≥ 70 ; ( Karnofsky &gt; 16 year Lansky ≤ 16 year age ) . Patients may nonbulky , asymptomatic metastatic disease . Males females must agree use effective birth control method course vaccination ( first vaccine two week last vaccine ) . Patients must free systemic infection require IV antibiotic time registration IV antibiotic least 7 day prior registration . Patients must adequate organ function measure : Bone marrow : ANC &gt; 1,000/µl ; Platelets &gt; 100,000/µl ( transfusion independent ) ; ALC ≥ 500/µl ; Hemoglobin &gt; 8 g/dl ( may transfuse ) . Hepatic : bilirubin ≤ 1.5x institutional normal age ; SGPT ( ALT ) &lt; 3x institutional normal Renal : Serum creatinine base age creatinine clearance radioisotope GFR &gt; 70 ml/min/1.73 m² Patients must recover toxic effect prior therapy least 3 week last dose standard cytotoxic chemotherapy myelosuppressive biological therapy , least one week last dose nonmyelosuppressive biological therapy least 4 week completion radiation therapy . Patients must overt cardiac , gastrointestinal , pulmonary , psychiatric disease . Patients must willing travel Pittsburgh receive vaccine . Visits : Every 3 week x 9 , every 6 week x 12 depend response/side effect Patients live outside North America eligible . Patients must concurrent treatment medication least 1 week include : Interferon ( e.g . IntronA® ) , allergy desensitization injetions , growth factor ( e.g . Pricrut® , Aranesp® , Neulasta® ) , interleukin ( e.g . Proleukin® ) , investigational therapeutic medication . Patients must history immune system disorder laboratory abnormality condition could potentially alter immune function . Use immunosuppressives within four week prior study entry anticipate use immunosuppressive agent . Patients must 0.1 mg/kg/day , max 4 mg/day dexamethasone least one week study registration . Topical corticosteroid acceptable . Patients know immune deficiency . Pregnancy breastfeed . Female patient postmenarchal must document negative pregnancy test . Tetanus vaccine therapy within 1 week prior enrollment . Patients receive prior immunotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>